147 related articles for article (PubMed ID: 31749296)
1. Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Desta Z; Gufford BT
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):40-47. PubMed ID: 31749296
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Gufford BT; Lu JBL; Bushman LR; Anderson PL; Bergstrom RF; Desta Z; Gupta SK
Clin Pharmacol Ther; 2020 May; 107(5):1200-1208. PubMed ID: 31675437
[TBL] [Abstract][Full Text] [Related]
3. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
5. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
6. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.
Ibrahim ME; Brooks KM; Castillo-Mancilla JR; McHugh C; Morrow M; Brothers J; MaWhinney S; Hosek S; Huhn G; Anderson PL
AIDS Res Hum Retroviruses; 2018 Oct; 34(10):835-837. PubMed ID: 30047286
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T
Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
9. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
10. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
11. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
12. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
13. Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
Drain PK; Kubiak RW; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Sukrakanchana PO; Tanasri S; Punyati P; Sirirungsi W; Cressey R; Bacchetti P; Okochi H; Baeten JM; Gandhi M; Cressey TR
Clin Infect Dis; 2020 May; 70(10):2143-2151. PubMed ID: 31314073
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
Yager JL; Anderson PL
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
17. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
18. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
19. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
20. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
